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Abstract 
Background 
Higher consumption of coffee intake has recently been linked with reduced risk of aggressive 
prostate cancer (PC) incidence, although meta-analysis of other studies that examine the 
association between coffee consumption and overall PC risk remains inconclusive. Only one 
recent study investigated the association between coffee intake and grade-specific incidence 
of PC, further evidence is required to understand the aetiology of aggressive PCs. Therefore, 
we conducted a prospective study to examine the relationship between coffee intake and 
overall as well as grade-specific PC risk. 
Methods 
We conducted a prospective cohort study of 6017 men who were enrolled in the 
Collaborative cohort study in the UK between 1970 and 1973 and followed up to 31st 
December 2007. Cox Proportional Hazards Models were used to evaluate the association 
between coffee consumption and overall, as well as Gleason grade-specific, PC incidence. 
Results 
Higher coffee consumption was inversely associated with risk of high grade but not with 
overall risk of PC. Men consuming 3 or more cups of coffee per day experienced 55% lower 
risk of high Gleason grade disease compared with non-coffee drinkers in analysis adjusted for 
age and social class (HR 0.45, 95% CI 0.23-0.90, p value for trend 0.01). This association 
changed a little after additional adjustment for Body Mass Index, smoking, cholesterol level, 
systolic blood pressure, tea intake and alcohol consumption. 
Conclusion 
Coffee consumption reduces the risk of aggressive PC but not the overall risk. 
Keywords 
Coffee, Prostate cancer, Incidence, Gleason grade, Risk factor 
Introduction 
Coffee is one of the most popular beverages worldwide and has been investigated for its role 
in PC development. Coffee compounds, diverse biologically active ingredients including 
caffeine, minerals and phytochemicals, have very strong metabolic, physiological, cellular 
and molecular effects [1]. Higher consumption of coffee for longer duration has been 
associated with improved glucose metabolism and insulin levels [2]. Also, growing evidence 
suggests that higher coffee consumption reduce the risk of diabetes mellitus [3,4], affect 
insulin like growth factors [5] and may alter the sex hormones [6,7]. Higher levels of 
circulating sex hormones, insulin like growth factors and insulin resistance are strongly 
associated with increased risk of PC [8-11]. Given, the beneficial effects of coffee 
consumption in lowering insulin resistance, insulin like growth factors and altering sex 
hormones may have some role in development of PC. 
Epidemiological evidence on coffee consumption and PC risk remains equivocal. A meta-
analysis of twelve epidemiological studies, including eight case–control and four prospective 
cohorts on the role of coffee in PC risk remained inconclusive [12]. There was a significant 
positive (harmful) association between higher coffee consumption and PC risk in case–
control studies (RR 1.21, 95% CI 1.03-1.43), whereas, no significant relationship was 
observed in cohort studies (RR 0.97, 95% CI 0.68-1.38) [12]. A more recent meta-analysis of 
five cohort studies suggested a reduced risk of PC (RR 0.79, 95% CI 0.61-0.98) among 
coffee drinker compared with non-drinkers [13]. Most of the epidemiological studies had 
smaller number of cases [14,15], retrospective study design [16-19] and all lacked 
information on disease stage and grade. 
Interestingly, a recent study on coffee consumption and PC risk from a large prospective 
cohort [20] reported a weak inverse association with overall risk and a strong inverse 
association between higher coffee intake and aggressive as well as lethal PC [20]. Authors 
concluded that higher coffee consumption can not be recommended to prevent PC and further 
epidemiological evidence on the association is required before making any recommendations. 
We therefore, investigated the association between coffee consumption and risk of overall as 
well as grade-specific PC from a large prospective cohort study with long follow up. 
Materials and methods 
The Collaborative study was the second of the Midspan studies which began in the 1960s and 
1970s in Scotland, UK [21]. In brief, the Collaborative study was conducted on employed 
men and women aged from 21 to 75 years from 27 workplaces in Glasgow, Clydebank and 
Grangemouth between 1970 and 1973 [22]. The response rate was 70% for these workplaces 
for which response rates were available (87% of the sample). 
Study protocols consisted of a self-administered questionnaire followed by a screening 
examination at a specially set-up clinic. Questions included demographic details, occupation 
and lifestyle habits. Daily coffee intake reported by the participants was categorised into three 
groups based on approximately equal number of participants in each group and also into two 
categories of coffee drinkers and non coffee drinkers. Weekly reported alcohol consumption 
was categorised by spirits, beer, and wine. This was converted to units of alcohol by taking 
one measure of spirits as 1 unit, 1 pint (0.6 litres) of beer as 2 units, and one bottle of wine as 
6 units [23]. Four categories of alcohol consumption were formed (none, 1–10, 11–21, > 21 
units of alcohol a week). As parts of the screening examination, measurements were made for 
height, weight and blood pressure. A blood sample was obtained at baseline screening for the 
measurement of total circulating plasma cholesterol. Body Mass Index (BMI) was calculated 
from weight (in kg) divided by height (in metres) squared and categorised according to the 
World Health Organisation classification in which BMI < 18.50 is underweight, 18.50 to < 25 
is the normal range, 25 to <30 is overweight and ≥30 is obese. We combined the underweight 
and normal BMI categories because the number of subjects was small in the underweight 
category and only one subject developed PC. Social class was derived from occupation 
according to the relevant version of the General Register Office Classification of Occupation 
[24] and graded into six categories: 
I (professional), II (intermediate), III non-manual (skilled non-manual), III manual (skilled 
manual), IV (partly skilled) and V (unskilled) [24]. Ex-smokers were defined as reporting 
giving up smoking at least a year before screening, otherwise they were defined as current 
smokers. Only the records for male participants were used for this study. 
Follow up for mortality was carried out by flagging Midspan participants with the National 
Health Service Central Register. Information on cancer registrations and hospital activity was 
obtained by linkage to the Scottish Morbidity Records (SMR) data [25]. Follow up began on 
the date of screening to the date of cancer incidence, date of death, date of embarkation 
(leaving the United Kingdom) or the censor date of 31st December 2007, whichever came 
first. 
Ethical approval 
The Privacy Advisory Committee of the Information Services Division of NHS Scotland 
gave permission for the linked data to be used in this study. 
Outcome definitions 
PC was defined as International Classification of Diseases (ICD) revision 9 codes 185 and 
ICD-10 codes C61. PC incidence was ascertained if it appeared in any of the records from 
cancer registration (SMR06), acute hospital record (SMR01) or death record. Where a patient 
had PC recorded on more than one type of record, the earliest date was taken as time of first 
diagnosis. The Gleason grading system is a method used to distinguish the morphology of 
clinical PC to provide prognostic information. Gleason score was recorded from 1st January 
1997 and therefore the analysis of grade-specific associations between coffee and PC was 
restricted to the follow up of the surviving cohort as of that date. 
Statistical analysis 
For coffee consumption categories, Cox proportional hazards models were used to estimate 
hazard ratios (HRs) for PC incidence from screening, and for specific histological grade from 
1st January 1997. Separate models were run for each Gleason category and men with PC and 
other Gleason scores were censored at their date of diagnosis. All analyses were conducted 
using STATA (stcox in STATA v11 StataCorp, College Station, TX, USA). Initial models 
were adjusted for age and social class. We then included smoking status, BMI, alcohol intake, 
coffee consumption, cholesterol level and systolic blood pressure in multivariate models. 
There were missing data for some covariates: 11 in social class; 41 in cholesterol level; 1 in 
height and weight; 1 in smoking status; and 1 in tea consumption. Total missing data for all 
covariates was less than 0.01% which did not change any of the associations when we ran the 
analysis both including those observations after imputations and excluding these individuals. 
We presented the final results after imputations in which missing information on continuous 
variables was replaced by the sample mean while for categorical variables missing data were 
replaced by modal values. The lowest category was used as referent for the coffee intake and 
all other categorical covariates. Adherence to the proportional hazards assumption was 
investigated by plotting smoothed Schoenfeld residuals against time; no violations of the 
assumption were identified. All statistical tests were two tailed and statistical significance 
was taken as p < 0.05. 
Results 
In total, data for 6022 men were available from the Collaborative Cohort Study for this 
analysis; five study participants were lost to follow up so they were excluded from the 
analysis. Our final sample comprised 6,017 men followed-up for a total of 155,383 person-
years. The median follow-up period was 28 years, maximum 37 years. Median age was 48 
years at the time of screening (range, 21–75 years). The mean follow-up time between 
screening and PC diagnosis was 25.8 (SD 10.58) years. 
Three hundred and eighteen men with PC were identified. Among 186 cancers that occurred 
from 1997 onward, 70 (37.6%) were high grade (Gleason score ≥ 8), 38 (20.4%) were 
intermediate grade (Gleason = 7), 41 (22.0%) low grade (Gleason ≤ 6) and the remaining 37 
(19.9%) were of unknown Gleason score. Individuals who had a normal BMI, higher social 
class and smokers were more likely to consume three or more cups of coffee per day while 
those taking high amount of alcohol were more likely to be low or non-coffee drinkers (Table 
1). 
Table 1 Baseline characteristics of 6017 male participants of the Collaborative cohort 
study at screening and prostate cancer outcome 
 Categories of cups of coffee/day 
 0 1--2 ≥ 3 
Sample Size 2,628  2,059  1,330  
Person-years of follow up 65,051  54,603  35,728  
Number of Deaths%(n) 70.3 (1848) 64.0 (1317) 62.0 (825) 
Number of men with prostate cancers%(n) 5.3 (139) 5.5 (114) 4.9 (65) 
Gleason grade ≥8 48.2 (39) 29.9 (20) 28.9 (11) 
Gleason grade =7 14.7 (12) 20.9 (14) 31.6 (12) 
Gleason grade <7 21.0 (17) 25.4 (17) 18.4 (7) 
Unknown 16.1 (13) 23.8 (16) 21.1 (8) 
Mean Age (s.d.) 48.2 (7.3) 47.5 (7.2) 46.8 (7.3) 
Mean Height (s.d.) 171.7 (6.9) 173.7 (7.1) 174.4 (6.8) 
Mean Weight (s.d.) 74.3 (10.7) 75.9 (10.7) 76.2 (10.2) 
Mean BMI (s.d.) 25.2 (3.2) 25.1 (3.0) 25.0 (2.9) 
BMI (kg m
-2
),%(n)       
<25 (Under & Desirable) 48.7 (1281) 49.3 (1015) 50.5 (671) 
25 – <30 (Overweight) 44.3 (1163) 45.3 (932) 44.8 (596) 
≥30 (Obese) 7.0 (184) 5.4 (112) 4.7 (63) 
Alcohol intake (units/week),%(n)       
0 24.2 (873) 29.7 (623) 36.4 (396) 
1—10 30.7 (606) 31.6 (683) 26.4 (451) 
11—21 22.0 (545) 19.8 (409) 20.2 (259) 
> 21 23.2 (604) 18.9 (344) 17.1 (224) 
Smoking,%(n)       
Never smoker 18.4 (483) 19.4 (400) 15.9 (211) 
Smoker 60.5 (1590) 53.0 (1091) 61.1 (812) 
Ex-smoker 21.1 (555) 27.6 (568) 23.1 (307) 
Social Class,%(n)       
I&II 18.3 (480) 41.0 (847) 51.1 (680) 
IIIN 29.0 (763) 15.1 (310) 11.0 (147) 
IIIM 17.9 (470) 20.4 (417) 17.1 (227) 
IV&V 34.8 (915) 23.5 (485) 20.8 (276) 
We found no convincing association between coffee and overall hazard of PC (Table 2), nor 
any consistent relationship within low and intermediate grade disease (Table 3). We also 
conducted further analyses excluding individuals diagnosed with PC in the first 10 years of 
screening (n = 14), after multivariate adjustments the inverse association between coffee 
consumption of ≥3 cups/day and reduced PC risk slightly changed (HR = 0.80, 95% CI 0.59-
1.10, p value 0.18) although remained non-significant. 
Table 2 Multivariate hazard ratios (HR) for overall prostate cancer by coffee 
consumption in 6017 men 
  All Prostate Cancers 
 Total n Hazard Ratio (95% CI)
a
 p value Hazard Ratio (95% CI)
b
 p value 
Cups of coffee/day           
0 2,628 (139) 1  1  
1--2 2,059 (114) 0.89 (0.69, 1.16) 0.39 0.95 (0.72, 1.24) 0.70 
≥3 1,330 (65) 0.81 (0.60, 1.09) 0.18 0.93 (0.66, 1.31) 0.66 
Cups of coffee (continuous) 6,017 (318) 0.95 (0.87, 1.02) 0.12 0.96 (0.81, 1.13) 0.64 
Age at screening           
< 40 823 (30) 1  1  
40-49 2,621 (129) 1.85 (1.24, 2.76) 0.003 1.73 (1.16, 2.59) 0.008 
50-59 2,424 (150) 4.49 (3.01, 6.68) <0.001 4.13 (2.74, 6.22) <0.001 
60-75 149 (9) 9.28 (4.36, 19.73) <0.001 8.21 (3.80, 17.72) <0.001 
Cholesterol level 6,017 (318) 1.02 (0.91, 1.14) 0.71 1.01 (0.91, 1.13) 0.80 
Systolic blood pressure 6,017 (318) 1.00 (0.99, 1.01) 0.83 0.99 (0.99, 1.01) 0.57 
BMI (kg m
-2
)           
<25 (Under & Desirable) 2,967 (152) 1  1  
25 – <30 (Overweight) 2,691 (148) 1.10 (0.88, 1.38) 0.41 1.11 (0.88, 1.40) 0.39 
≥30 (Obese) 359 (18) 1.25 (0.77, 2.05) 0.37 1.28 (0.77, 2.11) 0.34 
Alcohol intake (units/week)           
0 1,892 (115)  1    1   
1--10 1,740 (102) 0.97 (0.74, 1.27) 0.83 0.99 (0.75, 1.30) 0.92 
11--21 1,213 (52) 0.83 (0.60, 1.15) 0.28 0.87 (0.62, 1.22) 0.42 
> 21 1,172 (49) 0.94 (0.67, 1.32) 0.71 0.98 (0.69, 1.39) 0.92 
Smoking           
Never smoker 1,094 (68) 1  1  
Smoker 3,492 (136) 0.92 (0.71, 1.27) 0.59 0.93 (0.69, 1.26) 0.65 
Ex-smoker 1,430 (114) 1.43 (1.05, 1.93) 0.02 1.43 (1.05, 1.94) 0.02 
Social Class           
I&II 2,007 (122) 1  1  
IIIN 1,220 (68) 0.88 (0.64, 1.22) 0.45 0.97 (0.68, 1.39) 0.88 
IIIM 1,114 (75) 1.14 (0.85, 1.54) 0.38 1.16 (0.85, 1.58) 0.34 
IV&V 1,676 (53) 0.97 (0.73, 1.29) 0.83 1.02 (0.74, 1.39) 0.92 
Prostate cancer cases =318 
a = adjusted for age and social class, b = adjusted for age at screening, cholesterol, systolic 
blood pressure, BMI, alcohol intake, tea consumption, smoking status, social class. n = 
number of prostate cancer cases 
Table 3 Hazard ratios for overall and Gleason-specific prostate cancer by coffee 
consumption categories among 3527 men from the Collaborative cohort study who 
survived until 1
st
 January 1997 
   Cups of coffee per day P-value for 
trend 
  0 1--2 ≥3  
All prostate cancer     
 Total PC cases 81 67 38  
 Hazard Ratio (95% CI)
a
 reference 0.86 (0.62-1.20) 0.75 (0.50-1.11) 0.15 
 Hazard Ratio (95% CI)
b
 reference 0.84 (0.60-1.21) 0.74 (0.47-1.16) 0.23 
Gleason < 7     
 Total PC cases 17 17 07  
 Hazard Ratio (95% CI)
a
 reference 1.18 (0.59-2.35) 0.75 (0.30-1.87) 0.65 
 Hazard Ratio (95% CI)
b
 reference 1.04 (0.51-2.17) 0.54 (0.19-1.57) 0.48 
Gleason = 7     
 Total PC cases 12 14 12  
 Hazard Ratio (95% CI)
a
 reference 1.13 (0.51-2.50) 1.39 (0.60-3.22) 0.45 
 Hazard Ratio (95% CI)
b
 reference 1.23 (0.53-2.84) 1.79 (0.69-4.62) 0.17 
Gleason 8-10     
 Total PC cases 39 20 11  
 Hazard Ratio (95% CI)
a
 reference 0.52 (0.30-0.91) 0.45 (0.23-0.90) 0.01 
 Hazard Ratio (95% CI)
b
 reference 0.51 (0.28-0.92) 0.47 (0.22-1.01) 0.03 
Unknown Gleason     
 Total PC cases 13 16 08  
 Hazard Ratio (95% CI)
a
 reference 1.26 (0.59-2.69) 0.99 (0.40-2.49) 0.08 
 Hazard Ratio (95% CI)
b
 reference 1.17 (0.52-2.64) 0.88 (0.31-2.48) 0.89 
Prostate cancer cases =186 
a = adjusted for age and social class, b = adjusted for age at screening, cholesterol, systolic 
blood pressure, BMI, alcohol intake, tea intake, smoking status, social class 
Interestingly, the hazard reduced significantly from the no coffee consumption to the higher 
category of coffee intake (HR 0.45, 95% CI 0.23-0.90) among aggressive PC (Gleason 
score ≥ 8) after adjustment for age and social class. These associations changed a little after 
additional adjustment for BMI, smoking, tea consumption, alcohol intake, plasma cholesterol 
and systolic blood pressure and a progressive reduction in risk of high grade PC remained 
between no coffee consumption and other two categories of coffee intake (p value for trend 
0.03). However, the results were borderline significant which could be due to smaller number 
of cases (n = 11) in the highest category of coffee drinkers. We further investigated this 
association by combining the coffee categories as coffee drinkers and non-drinkers. Men who 
consumed any amount of coffee had significantly reduced risk of aggressive PC (HR 0.51, 
95% CI 0.29-0.87, p = 0.01) compared with non-coffee drinkers after adjustments for age, 
BMI, smoking, social class, tea consumption, alcohol intake, plasma cholesterol and systolic 
blood pressure (data not shown). 
Discussion 
We found that increased coffee intake was associated with reduced risk of aggressive PC but 
no significant relationship with either low grade (Gleason < 7), intermediate grade 
(Gleason = 7) and overall risk of developing PC in this population-based prospective cohort 
study. The men who drank 3 or more cups of coffee had 55% lower risk of developing 
aggressive disease (Gleason > 7). The overall null association between coffee consumption 
and PC incidence was consistent with many epidemiological studies [17-19]. Furthermore, 
inverse association between coffee and aggressive PC was fairly consistent with recently 
reported findings from Health Professional Follow-up Study, where a risk reduction of 47% 
was observed among high coffee consumers [20]. We are unaware of any other studies 
reporting the grade-specific PC risk in relation to coffee consumption. 
The demographic and lifestyle characteristics of high coffee drinkers i.e. higher social class, 
desirable BMIs and current smoking, make it unlikely that confounding is a major 
explanation for these findings. Confounding by smoking and other lifestyle factors would 
bias the results towards null rather than an inverse association, which we report. It might be 
hypothesised that reverse causality might explain the protective effect of coffee on PC 
reported elsewhere. That is, men with undiagnosed PC may reduce their fluid intake, 
including coffee, to reduce symptoms of polyuria. Thus, PC would be less frequent among 
men who drank more coffee. However, PC often produces no urinary symptoms because 
most of the tumours arise in the peripheral zone of the prostate gland [26]. In addition, we 
conducted analyses to assess possible reverse causation by excluding individuals who were 
diagnosed in the first 10 years of screening, interestingly the association between coffee and 
overall risk of PC, exaggerated after excluding men who were diagnosed in first 10 years of 
follow-up, although remained non-significant. 
Several biological mechanisms have been proposed which may explain the inverse 
association between high coffee consumption and aggressive PC. Coffee consumption can 
lower the insulin-like growth factor-1 (IGF-1) [5] which is associated with increased 
incidence of PC particularly high grade and advance stage disease [10,27]. Additionally, 
coffee is considered as a major source of antioxidants and many observational studies 
suggested that coffee consumption lower the inflammation [28,29]. There is growing 
evidence which suggests that inflammation play a vital role in the development of PC through 
the generation of proliferative inflammatory lesions [30]. Therefore, higher consumption of 
coffee may have a protective role in aggressive PC by reducing the inflammatory activity in 
tumour. 
Our findings are based on a prospective cohort study in the United Kingdom, with long 
follow up (median: 28 years, max. 37 years), lower losses to follow up (0.01%), adjustment 
for other lifestyle habits and information on Gleason grades of the diagnosed cases. Our study 
has some limitations. First, the Collaborative study questionnaire did not have information on 
family history of PC and other dietary intake history including lycopene, multivitamins, 
processed meat and calcium which have been linked with the risk of PC in many studies [31-
33]. Second, we relied on self reported coffee consumption at the time of screening which 
may suffer from information bias. Third, although reverse causation did not appear to explain 
our results, we can not rule it out as a possible source of bias. Fourth, PSA testing has 
remarkably influenced the incidence of PC in most Western countries including the United 
Kingdom, so any differences in low grade and high grade PC incidence may be because of 
screening differences between coffee drinkers and non-drinkers. Unfortunately, current 
cancer registry does not hold the information on PSA and we could not assess the screening 
differences between groups, which may explain the observed association. Sixth, the number 
of cases was small in this study, however this study had a fairly large sample compared to 
earlier prospective studies on coffee consumption and PC. Although grade-specific analysis 
was based on a smaller sub-group of cases, only one earlier study has investigated the coffee 
intake in relation to grade-specific PC incidence [20]. Given that the coffee consumption was 
assessed at baseline and the study had a fairly long follow-up, coffee intake among 
participants of this cohort may have changed considerably over time during the follow-up. 
This may have led to measurement error however; measurement error in this study is more 
likely to be non-differential and may have attenuated our results rather than exaggerated the 
association. Finally, any misclassification in coffee intake due to differences in cup size or 
type of coffee might bias our results. However, such misclassification would be expected to 
bias our results toward the null rather than the preventive association which we observed. 
Conclusion 
In conclusion, men who consumed coffee regularly experienced a reduced risk of aggressive 
PC. Our findings are important, given the lack of modifiable risk factors for PC and 
particularly for high grade disease. Further studies are required to examine this association 
with different types of coffee and with evaluation of stage and grade specific risks. 
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